University Of Texas System Board Of Regents, Texas; CP; Public Coll/Univ - Unlimited Student Fees Jun 10

  • ID: 2048068
  • June 2010
  • Region: Texas
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services assigned its 'AAA' long-term rating to the University of Texas System Board of Regents, Texas' $520 million series 2010D revenue financing system (RFS) taxable bonds. In addition, Standard & Poor's affirmed its 'AAA' long-term rating and 'A-1+' short-term rating on the system's outstanding RFS debt and commercial paper (CP) programs issued by the board. The outlook on the long-term rating is stable. The long-term rating reflects our view of the system's: Significant financial resources despite current market declines: Total endowment market values were estimated at $16.6 billion as of May 31, 2010, ranking it among the 25 largest higher-education endowments in the U.S., and include the separately held permanent university fund (PUF; $10.5 billion estimated...

Companies mentioned in this report are:
- Univ of Texas Sys Brd of Regents

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Univ of Texas Sys Brd of Regents

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.